Navellier & Associates’s TG Therapeutics TGTX Stock Holding History
Bought
Maintained
Sold
Other funds holding TGTX
Navellier & Associates's TGTX Position: Q3 2026 in Review
Navellier & Associates held its TG Therapeutics (TGTX) position steady in Q3 2026 at 29,290 shares worth $1.63M. The position accounts for 0.14% of the portfolio, ranked #146.
Navellier & Associates first reported a position in TGTX in Q1 2026 and has held it in 3 quarters since. 395 funds tracked by Wall St. Rank hold TGTX as of Q3 2026.
- Navellier & Associates held 29,290 shares of TG Therapeutics worth $1.63M as of Q3 2026.
- Navellier & Associates left its TG Therapeutics share count unchanged in Q3 2026.
- TG Therapeutics made up 0.14% of Navellier & Associates's portfolio in Q3 2026, its #146 holding.
- Navellier & Associates first reported a position in TG Therapeutics in Q1 2026 and has held it in 3 quarters since.
- 395 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2026.
Based on Navellier & Associates's 13F filing for Q3 2026, filed 12 Nov 2026.